在妇科瘤学中使用AKT抑制剂:过去,现在和未来
1Department of Obstetrics and Gynecology, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
AKT 抑制剂在妇科癌症中表现有前途,但面临挑战. 本综述探讨了最近的研究,以确定生物标志物,克服耐药性,并改进治疗策略,以获得更好的临床结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- PI3K/AKT/mTOR通路在癌症中至关重要,它调节了癌症的增殖,存活,新陈代谢和治疗耐药性.
- AKT 抑制剂正在开发中,有几种药物在临床试验中,显示出可变的抗瘤活性.
研究的目的:
- 系统地审查最近在妇科癌症中的AKT抑制剂 (AKTi) 研究.
- 为识别生物标志物,克服耐药性和开发AKTi治疗预后模型提供基础.
主要方法:
- 针对妇科癌症中AKT抑制剂的最新研究的系统性文献综述.
主要成果:
- 多种类型的AKT抑制剂正在开发中 (PH域竞争者,全osteric,ATP竞争).
- 早期临床结果显示,在精选的患者中,令人鼓舞的应答率和长期无进展生存 (PFS) 是令人鼓舞的.
- 挑战包括在更大的试验中确认疗效,管理毒性和阐明耐药性机制.
结论:
- 需要进一步的研究,以优化在妇科癌症AKTi治疗.
- 识别生物标志物和理解耐药性是改善临床翻译的关键.
- 本综述提供了洞察力,以指导未来的治疗策略和临床开发.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Inhibition of Cdk Activity
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
